Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cardiff Oncology, Inc. CRDF
$1.69
На 18:02, 12 мая 2023
+314.20%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
78631872.00000000
-
week52high
3.41
-
week52low
1.13
-
Revenue
386000
-
P/E TTM
-2
-
Beta
1.73702400
-
EPS
-0.93000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Baird | Outperform | Outperform | 29 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 09 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 28 февр 2022 г. |
| Baird | Outperform | 08 дек 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 10 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 16 сент 2022 г. |
| Piper Sandler | Overweight | Overweight | 13 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Erlander Mark | A | 24481 | 10000 | 25 ноя 2022 г. |
| White Lale | A | 113788 | 15000 | 19 сент 2022 г. |
| Armitage James O | A | 13000 | 13000 | 16 сент 2022 г. |
| Levine James E. | A | 60000 | 30000 | 16 сент 2022 г. |
| PACE GARY W | A | 644811 | 150000 | 15 сент 2022 г. |
| TANNENBAUM RENEE P | A | 10000 | 3600 | 15 сент 2022 г. |
| TANNENBAUM RENEE P | A | 6400 | 6400 | 15 сент 2022 г. |
| White Lale | D | 60716 | 28858 | 05 июл 2022 г. |
| White Lale | A | 98788 | 28858 | 05 июл 2022 г. |
| BRANCACCIO JOHN P | A | 125317 | 195 | 09 июн 2022 г. |
Новостная лента
Cardiff Oncology to Present at Upcoming Investor Conferences
PRNewsWire
21 ноя 2022 г. в 10:52
SAN DIEGO , Nov. 21, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in fireside chats and 1x1 investor meetings at the 34th Annual Piper Sandler Healthcare Conference and the JMP Securities Hematology and Oncology Summit taking place on November 29 – December 1, 2022, and December 6 – 7, 2022, respectively. Details of the fireside chats can be found below.
Cardiff Oncology to Present at the Jefferies London Healthcare Conference
PRNewsWire
08 ноя 2022 г. в 08:15
SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London, UK from November 15 – 17, 2022. Details of the presentation can be found below.
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 21:49
Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 25.93% and 24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment
Seeking Alpha
14 сент 2022 г. в 08:51
In a tremendous overreaction, Cardiff lost 41% of its value over the discontinuation of a prostate cancer trial on September 13, 2022,. Combined ESMO 2022 oncology conference reportings by Amgen, Mirati Therapeutics and Cardiff show Onvansertib is best-in-class in metastatic colorectal cancer, the lead indication.
Cardiff Oncology to Present at Upcoming Investor Conferences in September
PRNewsWire
08 сент 2022 г. в 08:15
SAN DIEGO , Sept. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Baird Global Healthcare Conference and the H.C.